IP Library Granted Patent US 10,596,158
Granted Patent B2
US 10,596,158 · App. 16/178,191 · Granted Mar 24, 2020

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Inventors: James Densmore Copp (Bargersville, IN); Ann W. Newman (Lafayette, IN); Anne Luong (Mississauga, CA)
Assignee: Akebia Therapeutics, Inc.
A61K31/444A61K9/14A61K9/2054A61K9/48A61K9/4866A61K31/4418C07D213/803C07D213/81C07B2200/13C07D221/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,596,158
App. No.
16/178,191
Granted
Mar 24, 2020
Kind
B2
Abstract

Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.

Claims (23)

1. A method for preparing a crystalline Compound (I):

a) preparing a solution of a Compound (I) in an organic solvent that is acetone;

b) bringing the solution to super-saturation to cause formation of crystals; and

c) isolating the crystals.

2. The method of claim 1 , wherein the crystalline Compound (I) has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3±2° 2θ.

3. The method of claim 1 , wherein the crystalline Compound (I) comprises less than 10% by weight of any other crystalline Compound (I).

4. The method of claim 3 , wherein the crystalline compound (I) comprises less than 5% by weight of any other crystalline Compound (I).

5. The method of claim 1 , wherein the crystalline compound comprises less than 10% by weight of amorphous Compound (I).

6. The method of claim 5 , wherein the crystalline compound (I) comprises less than 5% by weight of amorphous Compound (I).

7. The method of claim 1 , wherein the crystalline compound (I) has a DSC endotherm at about 175.8° C.

8. The method of claim 1 , wherein the crystalline compound (I) comprises less than 100 ppm of a compound of Formula (II),

as determined by GC/MS.

9. The method of claim 8 , wherein the crystalline compound (I) comprises less than 50 ppm of a compound of Formula (II).

10. The method of claim 9 , wherein the crystalline compound (I) comprises less than 10 ppm of a compound of Formula (II).

11. The method of claim 10 , wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.

12. The method of claim 1 , further comprising filtering the solution through a charcoal filter.

13. The method of claim 1 , wherein bringing the solution to super-saturation comprises addition of an anti-solvent that is water, allowing the solution to cool, and reducing the volume of the solution by evaporation, solvent exchange, or any combination thereof.

14. The method of claim 1 , further comprising washing the crystals.

15. The method of claim 14 , wherein the washing comprises washing with acetone or water, or any combination thereof.

16. The method of claim 14 , wherein the washing comprises washing with a combination of acetone and water.

17. The method of claim 1 , wherein isolating the crystals comprises filtering the crystals.

18. The method of claim 1 , further comprising drying the crystals under reduced pressure, optionally at an elevated temperature.

19. The method of claim 18 , wherein the drying is performed at a temperature of about 50° C.

Assignments (2)
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: COPP, JAMES DENSMORE; NEWMAN, ANN W.; LUONG, ANNE
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 049550/0705 →
Cited By (7)
US 12,269,802 US 12,419,877 US 12,478,615 US 12,569,474 US 12,612,367 US 12,629,357 US 12,673,919